We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

SAFC Announces Proligo Reagents at TIDES Conference

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

SAFC Supply Solutions, a member of the Sigma-Aldrich Group, has announced the launch of a cluster of Proligo Reagent products at the TIDES Oligonucleotide and Peptide Conference in Carlsbad, California.

The offerings include a line of four Pharmadite™ amidites for oligo-based drugs, a TFA C6 Linker, and key additions to the existing line-up of RNA amidites.

A key starting material for oligo-based drugs, Pharmadite amidites represent a class of standard protected DNA phosphoramidites with a controlled impurity profile, overall purity, and non-animal derived starting materials.

Prepared from DMT-protected nucleosides and a phosphitylating agent, the products include DMT-dA(bz) Pharmadite, DMT-dC(bz) Pharmadite, DMT-dG(ib) Pharmadite and DMT-dT Pharmadite.

The high level of control in the ISO 9001-certified manufacturing process at the SAFC-Hamburg production facility have allowed a purity specification of 99.5% for these materials.

Pharmadite products fulfil all the requirements for starting materials in the manufacture of active pharmaceutical ingredients as defined in the EMEA "Note for guidance on chemistry of the new active substance," making them suitable building blocks for oligonucleotide drugs.

Phosphoramidite technology is ideal for the modification of synthetic oligos with covalently attached linkers, and the Proligo Reagents trifluoroacetyl-protected amino linker is offered with a C6 spacer.

The base labile TFA group is removed during cleavage and deprotection. The amino linker is coupled with standard synthesis protocols, identical to the coupling of DNA monomer phosphoramidites.

Four products, including DMT-2’O-TBDMS-rA(bz), DMT-2’O-TBDMS-rC(ac), DMT-2’O-TBDMS-rG(ib) and DMT-2’O-TBDMS-rU, are now offered to the RNA market segment.

These products complement the existing SAFC Proligo TAC-protected RNA amidites, allowing the choice between using standard synthesis protocols or fast deprotection chemistries.

Commenting on the products, Dr. Andreas Wolter of SAFC Supply Solutions Proligo Reagents noted, "The new introductions at TIDES are strategic additions to a market-proven range."

"While carefully targeted for particular applications in the oligo market, they share the consistent quality, tight specifications and reliability required by our customers and traditionally available at our Hamburg manufacturing facility."